Nichols et al. found through the treatment with another SHP2 inhibitor, RMC-4550 (a small molecule allosteric inhibitor), that it reduces oncogenic RAS-RAF-MEK-ERK signaling and cancer growth by disrupting SOS1-mediated RAS-GTP loading, highlighting SHP2 inhibition as a promising molecular therapeutic strategy for nucleotide cycling oncogenic KRAS in cancer [45]. This evidence concerns the gene KRAS and cancer.